Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02994719 · ClinicalTrials.gov registry record
Gait Analysis in Neurological Disease
A clinical trial of Parkinson's Disease and Huntington Disease, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT02994719: Recruiting study of Parkinson's Disease and Huntington Disease, sponsored by Beth Israel Deaconess Medical Center.
NCT02994719 is a study of Parkinson's Disease and Huntington Disease that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 120 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02994719, a study of Parkinson's Disease and Huntington Disease, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate whether speed-dependent measures of gait can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.
Primary Outcome
Method of assessment: physiological parameter
Conditions Studied
Interventions
- DEVICE Deep Brain Stimulation
- DRUG Anti-Parkinson medication
Study Locations (1)
Massachusetts
- Clinical Research Center BIDMC - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2026-06-20 |
What NCT02994719 shows while recruiting
NCT02994719 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (81% lower).
The record links to 8 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Deep Brain Stimulation is the first listed.
NCT02994719 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02994719 about?
NCT02994719 is a clinical study titled "Gait Analysis in Neurological Disease". The purpose of this study is to investigate whether speed-dependent measures of gait can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.
What is the current status of trial NCT02994719?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2016-03-01. Estimated completion is 2026-06-20.
What conditions does trial NCT02994719 study?
This clinical trial studies the following conditions: Parkinson's Disease, Huntington Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration.
What interventions are being tested in trial NCT02994719?
The interventions under investigation include: Deep Brain Stimulation (DEVICE), Anti-Parkinson medication (DRUG).
Who is sponsoring clinical trial NCT02994719?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02994719 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02994719's enrollment target sits among peer trials
120 48th of 158 higher than 109 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease
RECRUITING
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease
RECRUITING · NA
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI